172 related articles for article (PubMed ID: 2491941)
1. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.
Mann JJ; Aarons SF; Wilner PJ; Keilp JG; Sweeney JA; Pearlstein T; Frances AJ; Kocsis JH; Brown RP
Arch Gen Psychiatry; 1989 Jan; 46(1):45-50. PubMed ID: 2491941
[TBL] [Abstract][Full Text] [Related]
2. l-Deprenyl in atypical depressives.
Quitkin FM; Liebowitz MR; Stewart JW; McGrath PJ; Harrison W; Rabkin JG; Markowitz J; Davies SO
Arch Gen Psychiatry; 1984 Aug; 41(8):777-81. PubMed ID: 6430257
[TBL] [Abstract][Full Text] [Related]
3. L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition.
Tariot PN; Cohen RM; Sunderland T; Newhouse PA; Yount D; Mellow AM; Weingartner H; Mueller EA; Murphy DL
Arch Gen Psychiatry; 1987 May; 44(5):427-33. PubMed ID: 3107514
[TBL] [Abstract][Full Text] [Related]
4. Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect?
Mendis N; Pare CM; Sandler M; Glover V; Stern GM
Psychopharmacology (Berl); 1981; 73(1):87-90. PubMed ID: 6785797
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
Amsterdam JD
J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131
[TBL] [Abstract][Full Text] [Related]
6. Biochemical effects of L-deprenyl in atypical depressives.
Liebowitz MR; Karoum F; Quitkin FM; Davies SO; Schwartz D; Levitt M; Linnoila M
Biol Psychiatry; 1985 May; 20(5):558-65. PubMed ID: 3921065
[TBL] [Abstract][Full Text] [Related]
7. Studies of selective and reversible monoamine oxidase inhibitors.
Mann JJ; Aarons SF; Frances AJ; Brown RD
J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
[TBL] [Abstract][Full Text] [Related]
8. High-dose selegiline in treatment-resistant older depressive patients.
Sunderland T; Cohen RM; Molchan S; Lawlor BA; Mellow AM; Newhouse PA; Tariot PN; Mueller EA; Murphy DL
Arch Gen Psychiatry; 1994 Aug; 51(8):607-15. PubMed ID: 7519005
[TBL] [Abstract][Full Text] [Related]
9. L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation.
Mendlewicz J; Youdim MB
Br J Psychiatry; 1983 May; 142():508-11. PubMed ID: 6409196
[TBL] [Abstract][Full Text] [Related]
10. The relative efficacy of l-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression.
Mann JJ; Frances A; Kaplan RD; Kocsis J; Peselow ED; Gershon S
J Clin Psychopharmacol; 1982 Feb; 2(1):54-7. PubMed ID: 6802883
[No Abstract] [Full Text] [Related]
11. Tyramine pressor sensitivity changes during deprenyl treatment.
Sunderland T; Mueller EA; Cohen RM; Jimerson DC; Pickar D; Murphy DL
Psychopharmacology (Berl); 1985; 86(4):432-7. PubMed ID: 3929314
[TBL] [Abstract][Full Text] [Related]
12. Deprenyl in Parkinson disease.
Eisler T; Teräväinen H; Nelson R; Krebs H; Weise V; Lake CR; Ebert MH; Whetzel N; Murphy DL; Kopin IJ; Calne DB
Neurology; 1981 Jan; 31(1):19-23. PubMed ID: 6161320
[TBL] [Abstract][Full Text] [Related]
13. A placebo-controlled trial of L-deprenyl in atypical depression.
McGrath PJ; Stewart JW; Harrison W; Wager S; Nunes EN; Quitkin FM
Psychopharmacol Bull; 1989; 25(1):63-7. PubMed ID: 2505303
[No Abstract] [Full Text] [Related]
14. Absence of "cheese effect" during deprenyl therapy: some recent studies.
Sandler M; Glover V; Ashford A; Stern GM
J Neural Transm; 1978; 43(3-4):209-15. PubMed ID: 745013
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of deprenyl, a specific inhibitor of MAOB.
Psychopharmacol Bull; 1983; 19(3):328-42. PubMed ID: 6314420
[No Abstract] [Full Text] [Related]
16. Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline).
Murphy DL; Karoum F; Pickar D; Cohen RM; Lipper S; Mellow AM; Tariot PN; Sunderland T
J Neural Transm Suppl; 1998; 52():39-48. PubMed ID: 9564606
[TBL] [Abstract][Full Text] [Related]
17. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
18. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
Presthus J; Berstad J; Lien K
Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
[TBL] [Abstract][Full Text] [Related]
19. Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy.
Lee DH; Mendoza M; Dvorozniak MT; Chung E; van Woert MH; Yahr MD
J Neural Transm Park Dis Dement Sect; 1989; 1(3):189-94. PubMed ID: 2505797
[TBL] [Abstract][Full Text] [Related]
20. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
Riederer P; Youdim MB
J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
